Screener
Allogene Therapeutics ALLO Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $30,309 | $51,688 |
| Short-term investments | 236,577 | 198,522 |
| Prepaid expenses and other current assets | 6,407 | 7,539 |
| Total current assets | 273,293 | 257,749 |
| Long-term investments | — | 8,043 |
| Operating lease right-of-use asset | 38,819 | 39,888 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's short-term investments?
- Allogene Therapeutics (ALLO) reported short-term investments of $236.58M in Q1 2026.
- How has Allogene Therapeutics's short-term investments changed year-over-year?
- Allogene Therapeutics's short-term investments decreased by 0.4% year-over-year, from $237.59M to $236.58M.
- What is the long-term trend for Allogene Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Allogene Therapeutics's short-term investments has grown at a -21.0% compound annual growth rate (CAGR), from $644.56M to $198.52M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Allogene Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude